Sumitomo Mitsui Asset Management Company LTD held its position in shares of Mednax, Inc (NYSE:MD) during the second quarter, Holdings Channel reports. The fund owned 6,980 shares of the company’s stock at the end of the second quarter. Sumitomo Mitsui Asset Management Company LTD’s holdings in Mednax were worth $421,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. First Citizens Bank & Trust Co. purchased a new position in shares of Mednax during the first quarter valued at $357,000. American Capital Management Inc. boosted its position in shares of Mednax by 1.0% in the first quarter. American Capital Management Inc. now owns 294,735 shares of the company’s stock valued at $20,449,000 after buying an additional 2,790 shares during the last quarter. GW Henssler & Associates Ltd. boosted its position in shares of Mednax by 12.7% in the first quarter. GW Henssler & Associates Ltd. now owns 152,837 shares of the company’s stock valued at $10,604,000 after buying an additional 17,183 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in shares of Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock valued at $158,000 after buying an additional 102 shares during the last quarter. Finally, Retirement Systems of Alabama boosted its position in shares of Mednax by 0.9% in the first quarter. Retirement Systems of Alabama now owns 175,089 shares of the company’s stock valued at $12,148,000 after buying an additional 1,477 shares during the last quarter.

Shares of Mednax, Inc (NYSE:MD) opened at 42.10 on Friday. The company has a 50-day moving average of $54.64 and a 200 day moving average of $61.63. Mednax, Inc has a one year low of $41.90 and a one year high of $72.13. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 13.41 and a beta of 0.40.

Mednax (NYSE:MD) last issued its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm had revenue of $843 million for the quarter, compared to analyst estimates of $849.49 million. During the same period last year, the company earned $1.03 EPS. The firm’s quarterly revenue was up 9.2% on a year-over-year basis. Equities research analysts forecast that Mednax, Inc will post $3.31 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Mednax, Inc (MD) Stake Maintained by Sumitomo Mitsui Asset Management Company LTD” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/mednax-inc-md-stake-maintained-by-sumitomo-mitsui-asset-management-company-ltd/1472074.html.

Several brokerages have recently weighed in on MD. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Thursday, April 13th. Jefferies Group LLC reissued a “hold” rating and set a $58.00 price target on shares of Mednax in a research report on Wednesday, April 26th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $55.00 to $68.00 in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $64.00.

In other Mednax news, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the sale, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.